Lonza Withdraws Bid to Acquire Patheon

Lonza says it has withdrawn its previously announced non-binding proposal to acquire all of the outstanding restricted voting shares of pharmaceutical contract manufacturing and development services company Patheon (Toronto), due to “a combination of factors including value considerations, and the rejection of the Lonza proposal by the majority shareholder of Patheon.”  The proposal was rejected by private equity firm JLL Partners (New York), which owns 57% of Patheon, say press reports. Lonza submitted a non-binding proposal, in August, to...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers